Frontier Asset Management’s AbbVie ABBV Stock Holding History

Frontier Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.76M	Sell	10,976 -1,575	-13%	-$339K	0.49%	31
2026 Q1	$2.73M	Buy	12,551 +136	+1%	+$30.2K	0.57%	30
2025 Q4	$2.84M	Sell	12,415 -12,545	-50%	-$2.86M	0.66%	30
2025 Q3	$5.78M	Sell	24,960 -138	-0.5%	-$28.1K	1.44%	23
2025 Q2	$4.66M	Buy	25,098 +230	+0.9%	+$42.7K	1.27%	24
2025 Q1	$5.21M	Hold	24,868	–	–	1.51%	22
2024 Q4	$4.42M	Sell	24,868 -7	-0%	-$1.29K	1.46%	23
2024 Q3	$4.91M	Hold	24,875	–	–	1.63%	20
2024 Q2	$4.27M	Hold	24,875	–	–	1.55%	20
2024 Q1	$4.53M	Buy	24,875 +7	+0%	+$1.21K	1.66%	18
2023 Q4	$3.85M	Hold	24,868	–	–	1.45%	19
2023 Q3	$3.71M	Buy	24,868 +108	+0.4%	+$15.9K	1.68%	17
2023 Q2	$3.34M	Sell	24,760 -606	-2%	-$88.9K	1.52%	19
2023 Q1	$4.04M	Buy	25,366 +242	+1%	+$37K	1.91%	19
2022 Q4	$4.06M	Buy	25,124 +239	+1%	+$36.6K	1.86%	17
2022 Q3	$3.34M	Buy	24,885 +125	+0.5%	+$17.9K	2.9%	12
2022 Q2	$3.79M	Sell	24,760 -109	-0.4%	-$16.7K	3.16%	10
2022 Q1	$4.03M	Hold	24,869	–	–	2.83%	14
2021 Q4	$3.37M	Buy	+24,869	New	+$2.94M	2.48%	14

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Frontier Asset Management's ABBV Position: Q2 2026 in Review

Frontier Asset Management reduced its AbbVie (ABBV) stake by 13% in Q2 2026, selling an estimated $339K and leaving 10,976 shares worth $2.76M. The position accounts for 0.49% of the portfolio, ranked #31.

Frontier Asset Management first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. The position peaked at $5.78M in Q3 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Frontier Asset Management held 10,976 shares of AbbVie worth $2.76M as of Q2 2026.
Frontier Asset Management sold 1,575 AbbVie shares in Q2 2026, an estimated $339K.
AbbVie made up 0.49% of Frontier Asset Management's portfolio in Q2 2026, its #31 holding.
Frontier Asset Management first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
Frontier Asset Management's AbbVie position peaked at $5.78M in Q3 2025.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Frontier Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.